Showing 8481-8490 of 9758 results for "".
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459201/
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- Clinical Trials Designed to Block Autophagy in Multiple Cancers, Including Melanoma, Show Promisehttps://practicaldermatology.com/news/20140606-clinical_trials_designed_to_block_autophagy_in_multiple_cancers_including_melanoma_show_promise/2459217/
- Synera Approved for At-Home Use to Prevent Needle Stick Discomforthttps://practicaldermatology.com/news/20140604-synera_approved_for_at-home_use_to_prevent_needle_stick_discomfort/2459219/
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/
- Registration Open for Upcoming ADAM Webinarshttps://practicaldermatology.com/news/20140521-registration_open_for_upcoming_adam_webinars/2459233/
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of